Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 5/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.43 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.43 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.43 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.43 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.43 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.43 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.43 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16432180 | 0.84 | PTGS1 (0.49) | KDM4EPOLBUSP2HSD17B10NPC1 | |
| SCHEMBL28626652 | 0.81 | MAPT (0.43) | KDM4EPOLBUSP2HSD17B10NPC1 | |
| SCHEMBL14204739 | 0.80 | CYP3A4 (0.46) | KDM4EPOLBNPC1HSP90AA1MAPT | |
| SCHEMBL16401877 | 0.79 | GAA (0.42) | KDM4EPOLBNPC1HSP90AA1MAPT | |
| SCHEMBL7414983 | 0.76 | GAA (0.46) | KDM4EPOLBHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL2422146 | 0.76 | KDM4E (0.48) | KDM4EPOLBHSD17B10NPC1HSP90AA1 | |
| SCHEMBL14372984 | 0.76 | KDM4E (0.39) | KDM4EPOLBUSP2HSD17B10NPC1 | |
| SCHEMBL19125185 | 0.75 | MAPT (0.43) | KDM4EPOLBHSD17B10NPC1HSP90AA1 | |
| SCHEMBL645223 | 0.75 | CNR2 (0.49) | KDM4EPOLBNPC1HSP90AA1MAPT | |
| SCHEMBL16429697 | 0.75 | TNKS (0.57) | KDM4EPOLBNPC1HSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | KDM4E 1790/4885POLB 4200/4885USP2 4260/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | KDM4E 1790/4885POLB 4200/4885USP2 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.